A5208

Optimal Combination Therapy After Nevirapine Exposure (OCTANE)

Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID)

Protocol Summary: A5208 was a phase III study that comprised of two randomized clinical trials that were conducted concurrently. Both compared the virologic response to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based versus protease inhibitor (PI)-based antiretroviral treatment (ART) in HIV-infected, treatment-naïve women. Trial 1 evaluated the superiority of PI-based ART over NNRTI-based ART in women with prior single-dose (SD) nevirapine (NVP) prophylaxis for mother-to-child-transmission (MTCT) of HIV. Trial 2 evaluated the equivalence of PI- and NNRTI-based ART in women with no prior NVP exposure.

Years: 2007 – 2011

Investigator: Tsungai Chipato, MBChB, FRCOG, MCE

Location: Parirenyatwa CRS

Comments are closed.